<DOC>
	<DOC>NCT00388440</DOC>
	<brief_summary>To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore. The vaccine was administered as a single dose to healthy children (12-18 months of age) and blood samples were collected at two time points (before vaccination and after vaccination).</brief_summary>
	<brief_title>Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male or female infant between 12 and 18 months of age at the time of the vaccination Written informed consent obtained from the parents or guardians of the subject. Free of obvious health problems as established by medical history and clinical examination before entering into the study. Use of any investigational or nonregistered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the dose of study vaccine Previous vaccination against mumps and/or rubella History of, or intercurrent, measles, mumps, and/or rubella disease Known exposure to measles, mumps or rubella within 30 days prior to the start of the study Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mumps</keyword>
	<keyword>Singapore</keyword>
	<keyword>Rubella</keyword>
	<keyword>Measles</keyword>
</DOC>